CYTOKINETICS, INCORPORATED Deferred Revenue, Revenue Recognized (Deprecated 2016-01-31)
CYTOKINETICS, INCORPORATED (CYTK) reported Deferred Revenue, Revenue Recognized (Deprecated 2016-01-31) of $1.40 million for the 9-month period ending 2013-09-30, per its 10-Q filed 2013-11-06.
Discontinued › Income Statement › Other Income
us-gaap:DeferredRevenueRevenueRecognized · last filed 2013-11-06
- 2013-09-30: Deferred Revenue, Revenue Recognized (Deprecated 2016-01-31) 9 month $1.40M.
| Period end | Deferred Revenue, Revenue Recognized (Deprecated 2016-01-31) 9 month |
|---|---|
| 2013-09-30 | $1.40M 10-Q · filed 2013-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |